CL2018003403A1 - Composiciones antineoplásicas. - Google Patents

Composiciones antineoplásicas.

Info

Publication number
CL2018003403A1
CL2018003403A1 CL2018003403A CL2018003403A CL2018003403A1 CL 2018003403 A1 CL2018003403 A1 CL 2018003403A1 CL 2018003403 A CL2018003403 A CL 2018003403A CL 2018003403 A CL2018003403 A CL 2018003403A CL 2018003403 A1 CL2018003403 A1 CL 2018003403A1
Authority
CL
Chile
Prior art keywords
castration
cancer
resistant
prostate cancer
copylimer
Prior art date
Application number
CL2018003403A
Other languages
English (en)
Inventor
Johny Bertels
Jurgen Mensch
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56148120&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018003403(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of CL2018003403A1 publication Critical patent/CL2018003403A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FORMULACIONES FARMACÉUTICAS DE ACETATO DE ABIRATERONA Y ARN-509, QUE SE PUEDEN ADMINISTRAR A MAMÍFEROS, EN PARTICULAR A HUMANOS, QUE SUFREN DE UNA ENFERMEDAD O AFECCIÓN RELACIONADA CON UN RECEPTOR ANDROGÉNICO (AR), EN PARTICULAR, CÁNCER, MÁS PARTICULARMENTE, CÁNCER DE PRÓSTATA, QUE INCLUYE ENTRE OTROS, CÁNCER DE PRÓSTATA RESISTENTE A LA CASTRACIÓN, CÁNCER DE PRÓSTATA METASTÁSICO RESISTENTE A LA CASTRACIÓN, CÁNCER DE PRÓSTATA METASTÁSICO RESISTENTE A LA CASTRACIÓN EN PACIENTES QUE NO HAN RECIBIDO QUIMIOTERAPIA, CÁNCER DE PRÓSTATA SENSIBLE A HORMONAS RECIDIVANTES BIOQUÍMICAMENTE O CÁNCER DE PRÓSTATA NO METASTÁSICO RESISTENTE A LA CASTRACIÓN DE ALTO RIESGO. EN UN ASPECTO, ESTAS FORMULACIONES COMPRENDEN ACETATO DE ABIRATERONA Y UNA DISPERSIÓN SÓLIDA DE ARN-509 Y UN POLÍMERO SELECCIONADO ENTRE HPMCAS, UN COPOLÍMERO DE POLI(META)ACRILATO Y MEZCLAS DE ESTOS. EN UN ASPECTO, ESTAS FORMULACIONES COMPRENDEN UN GRANULADO DE ACETATO DE ABIRATERONA Y UNA DISPERSIÓN SÓLIDA DE ARN-509 Y UN POLÍMERO SELECCIONADO ENTRE HPMCAS, UN COPOLÍMERO DE POLI(META)ACRILATO Y MEZCLAS DE ESTOS.
CL2018003403A 2016-06-03 2018-11-29 Composiciones antineoplásicas. CL2018003403A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16172968 2016-06-03

Publications (1)

Publication Number Publication Date
CL2018003403A1 true CL2018003403A1 (es) 2019-02-01

Family

ID=56148120

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003403A CL2018003403A1 (es) 2016-06-03 2018-11-29 Composiciones antineoplásicas.

Country Status (24)

Country Link
US (1) US20190216829A1 (es)
EP (1) EP3463377A1 (es)
JP (1) JP2019517497A (es)
KR (1) KR20190015314A (es)
CN (1) CN109219437A (es)
AR (1) AR108489A1 (es)
AU (1) AU2017275396A1 (es)
BR (1) BR112018074965A2 (es)
CA (1) CA3024872A1 (es)
CL (1) CL2018003403A1 (es)
CO (1) CO2018012857A2 (es)
CR (1) CR20180600A (es)
EA (1) EA201892828A1 (es)
IL (1) IL263157A (es)
MA (1) MA45090A (es)
MX (1) MX2018014846A (es)
NI (1) NI201800127A (es)
PE (1) PE20181925A1 (es)
PH (1) PH12018502334A1 (es)
SG (1) SG11201809680QA (es)
TN (1) TN2018000366A1 (es)
TW (1) TW201808287A (es)
UA (1) UA124154C2 (es)
WO (1) WO2017209939A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2883187T3 (es) * 2014-12-05 2021-12-07 Aragon Pharmaceuticals Inc Composiciones anticancerosas
CZ2016573A3 (cs) 2016-09-16 2018-03-28 Zentiva, K.S. Pevná formulace abirateronu acetátu vyráběná technologií fluidní granulace
CN109125276A (zh) * 2017-06-19 2019-01-04 齐鲁制药有限公司 一种醋酸阿比特龙片剂的药物组合物及其制备方法
US20200397756A1 (en) * 2018-02-09 2020-12-24 Kashiv Biosciences, Llc A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens
EP3784218A1 (en) 2018-04-26 2021-03-03 Synthon B.V. Tablet compositions comprising abiraterone acetate
US20220257613A1 (en) * 2019-07-15 2022-08-18 Shilpa Medicare Ltd Dispersible tablets of abiraterone acetate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ249911A (en) 1992-03-31 1996-06-25 British Tech Group 17-(3-pyridyl) substituted steroids and use in pharmaceutical compositions
JP6182209B2 (ja) 2012-06-07 2017-08-16 アラゴン ファーマシューティカルズ，インコーポレイテッド アンドロゲン受容体変調剤の結晶質形態
ES2741800T3 (es) * 2013-03-15 2020-02-12 Sun Pharma Global Fze Formulación de acetato de abiraterona
US20160346207A1 (en) * 2014-02-05 2016-12-01 Lek Pharmaceuticals D.D. Solid Pharmaceutical Compositions Of Androgen Receptor Antagonists
TWI718102B (zh) * 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體

Also Published As

Publication number Publication date
EA201892828A1 (ru) 2019-05-31
MA45090A (fr) 2021-04-28
EP3463377A1 (en) 2019-04-10
SG11201809680QA (en) 2018-11-29
CA3024872A1 (en) 2017-12-07
US20190216829A1 (en) 2019-07-18
BR112018074965A2 (pt) 2019-03-12
AU2017275396A1 (en) 2018-11-22
TW201808287A (zh) 2018-03-16
IL263157A (en) 2018-12-31
KR20190015314A (ko) 2019-02-13
MX2018014846A (es) 2019-03-14
CR20180600A (es) 2019-07-11
UA124154C2 (uk) 2021-07-28
WO2017209939A1 (en) 2017-12-07
PH12018502334A1 (en) 2019-07-29
CO2018012857A2 (es) 2018-12-14
AR108489A1 (es) 2018-08-29
CN109219437A (zh) 2019-01-15
NI201800127A (es) 2019-03-29
PE20181925A1 (es) 2018-12-11
TN2018000366A1 (en) 2020-06-15
JP2019517497A (ja) 2019-06-24

Similar Documents

Publication Publication Date Title
CL2018003403A1 (es) Composiciones antineoplásicas.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
EP4344706A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
TN2016000094A1 (en) Inhibitors of bruton's tyrosine kinase.
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
PH12017500979A1 (en) Anticancer compositions
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
MY191407A (en) Certain chemical entities, compositions and methods
PH12017500964A1 (en) Anticancer compositions
EP3838298A3 (en) Psma binding ligand-linker conjugates and methods for using
MX343405B (es) Complejos que emiten alfa-particulas objetivo que comprenden radionuclido de torio e hidroxipiridinona que contiene ligando.
MX337590B (es) Anticuerpos anti il-6 humanos, con semivida in vivo prolongada y su uso en el tratamiento de oncologia, enfermedades autoinmunes y enfermedades inflamatorias.
JO3776B1 (ar) التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
EP2544667A4 (en) ALCOHOL-RESISTANT PHARMACEUTICAL COMPOSITIONS
WO2012024530A3 (en) Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
AR102924A1 (es) Composiciones anticancerosas
MX345697B (es) Formulaciones de rifaximina y usos de las mismas.
NZ723860A (en) Pharmaceutical compositions of therapeutically active compounds and their uses
MX2019013693A (es) Bis-octahidrofenantreno carboxamidas y conjugados de proteinas de las mismas.
MX2015008021A (es) Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
MX371343B (es) Moduladores del receptor x hepatico (lxr).